Most pharma organizations consider ‘data’ as a key focus area to forge emerging business models by harnessing its immense potential. Data is crucial to fulfilling critical decision making across the Pharma value chain. Today, IT functions in most organizations focus on areas such as data governance, data quality, access management, model configuration, etc. along with data maintenance, processing, and storage. A robust data management solution is a critical IT requirement across pharma organizations. With the advent of cloud infrastructure and new-age technologies, most of the pharma organizations are now preferring advanced next-generation data management solutions for cleaned, integrated and streamlined data on-demand, along with intelligent insights, leading to better decision-making driving long-term profitability.
In addition to Axtria’s presentations and posters (discussed in our first blog on Axtria’s participation in PMSA’s 2018 Annual Conference), Axtria’s Principal, Devesh Verma, Ph.D., will be moderating a Next Generation Analytics Panel Discussion with roundtable participation. This session will take place on Tuesday, May 1, at 3:30 p.m.
As part of Axtria’s exciting presentation lineup, David Wood, Senior Principal, and Shubham Lahoti, Associate Director, will be presenting on the topic of “Measuring Direct and Indirect Influence of Account Managers”.
We are excited to announce that Axtria will be participating in the Pharmaceutical Management Science Association’s (PMSA) annual conference yet again. This year’s theme is “Next Generation Analytics.”
Estimating the size of a target patient population is critical for many stakeholders within the healthcare industry. For pharmaceutical companies, a strong understanding of the patient population should feed into research & development, forecasting, physician targeting, and discussions with payers and health technology authorities (HTAs). For payers, the size of the target patient population aids in estimating the budget impact of treatments and the overall burden of disease.
In patients with high cardiovascular risk, statins are the first-line of therapy. Statins, such as Crestor® and Lipitor®, are economical and effective. However, for those patients who do not have a good response to statins, or those patients with genetic disorders that require aggressive cholesterol lowering, treatment with PCSK9is is an option.
We all know that in sales, the outcomes you get are the outcomes you incent. This is especially important for large field forces such as pharma, where a very large number of influencers are being targeted and sales compensation is computed based on terabytes of external data! Good incentive compensation (IC) plans combined with well administered execution can motivate the sales force and drive the right behaviors to align with corporate goals. But how do we know if the measures we’ve selected contribute to an intelligent incentive plan design?
Effective roster management has long been an overlooked topic in Pharma commercial operations. In fact, in our 2016 Commercial Excellence Survey, we found that 46% of Pharma organizations still don’t have integrated processes to manage their sales rep to territory mappings. At any point in time, it is critical for the Sales Operations business processes to have access to the latest and distinct set of sales personnel that will need to be accounted for.
Axtria conducted a workshop on Multi-Channel Marketing and Next Generation Engagement at the PMSA January Symposium in Las Vegas.
Axtria is extremely proud to rank in the CIOReview Tech Solution Providers list for 2017, which is an annual listing of 20 companies that are at the forefront of providing Pharma and Life Science solutions and impacting the market.